Posted by Michael Wonder on 25 Jul 2022
Tezspire recommended for approval in the EU by CHMP for the treatment of severe asthma
25 July 2022 - First and only biologic recommended for EU approval in patients with severe asthma with no phenotype or biomarker limitations
AstraZeneca’s Tezspire (tezepelumab) has been recommended for marketing authorisation in the European Union as an add-on therapy in patients 12 years and older with severe asthma who are inadequately controlled with high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
